JP2025505229A - 稀少遺伝性肥満症の予防または治療におけるメラノコルチン-4受容体アゴニストの使用 - Google Patents

稀少遺伝性肥満症の予防または治療におけるメラノコルチン-4受容体アゴニストの使用 Download PDF

Info

Publication number
JP2025505229A
JP2025505229A JP2024547302A JP2024547302A JP2025505229A JP 2025505229 A JP2025505229 A JP 2025505229A JP 2024547302 A JP2024547302 A JP 2024547302A JP 2024547302 A JP2024547302 A JP 2024547302A JP 2025505229 A JP2025505229 A JP 2025505229A
Authority
JP
Japan
Prior art keywords
formula
acid
compound
pharma
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547302A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505229A5 (cg-RX-API-DMAC7.html
Inventor
ヒ・ドン・パク
ヒェ・キョン・ファン
ス・ジン・ヨ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Chem Ltd
Original Assignee
LG Chem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LG Chem Ltd filed Critical LG Chem Ltd
Publication of JP2025505229A publication Critical patent/JP2025505229A/ja
Publication of JP2025505229A5 publication Critical patent/JP2025505229A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024547302A 2022-02-08 2023-02-07 稀少遺伝性肥満症の予防または治療におけるメラノコルチン-4受容体アゴニストの使用 Pending JP2025505229A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20220016377 2022-02-08
KR10-2022-0016377 2022-02-08
PCT/KR2023/001712 WO2023153762A1 (ko) 2022-02-08 2023-02-07 멜라노코르틴-4 수용체 효능제의 희귀성 유전적 비만질환의 예방 또는 치료에서의 용도

Publications (2)

Publication Number Publication Date
JP2025505229A true JP2025505229A (ja) 2025-02-21
JP2025505229A5 JP2025505229A5 (cg-RX-API-DMAC7.html) 2026-02-17

Family

ID=87564659

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547302A Pending JP2025505229A (ja) 2022-02-08 2023-02-07 稀少遺伝性肥満症の予防または治療におけるメラノコルチン-4受容体アゴニストの使用

Country Status (13)

Country Link
US (1) US20250134898A1 (cg-RX-API-DMAC7.html)
EP (1) EP4461297A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505229A (cg-RX-API-DMAC7.html)
KR (1) KR20230120106A (cg-RX-API-DMAC7.html)
CN (1) CN119300835A (cg-RX-API-DMAC7.html)
AR (1) AR128463A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023218785A1 (cg-RX-API-DMAC7.html)
CA (1) CA3248118A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002389A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024011882A2 (cg-RX-API-DMAC7.html)
MX (1) MX2024009854A (cg-RX-API-DMAC7.html)
TW (1) TWI838114B (cg-RX-API-DMAC7.html)
WO (1) WO2023153762A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3202315A1 (en) * 2020-12-22 2022-06-30 Hee Dong Park Use as selective agonist of malanocortin-4 receptor
KR20250046623A (ko) * 2023-09-27 2025-04-03 주식회사 엘지화학 멜라노코르틴-4 수용체 효능제의 pcsk1 결핍 적응증과 연관된 희귀성 유전적 비만질환의 예방 또는 치료 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI332501B (en) * 2006-07-14 2010-11-01 Lg Life Sciences Ltd Melanocortin receptor agonists
US12516047B2 (en) * 2019-11-07 2026-01-06 Lg Chem, Ltd. Melanocortin-4 receptor agonists
CN116507615A (zh) * 2020-10-29 2023-07-28 株式会社Lg化学 黑皮质素受体激动剂化合物的晶型i及其制备方法
TWI804170B (zh) * 2021-01-21 2023-06-01 南韓商Lg化學股份有限公司 黑皮質素-4受體促效劑的用途
TWI826938B (zh) * 2021-02-26 2023-12-21 南韓商Lg化學股份有限公司 黑皮質素-4受體促效劑
TWI861780B (zh) * 2022-03-28 2024-11-11 南韓商Lg化學股份有限公司 預防或治療肥胖的聯合療法

Also Published As

Publication number Publication date
AU2023218785A1 (en) 2024-08-22
CA3248118A1 (en) 2025-01-24
WO2023153762A1 (ko) 2023-08-17
EP4461297A4 (en) 2025-04-09
CL2024002389A1 (es) 2025-01-31
TW202339761A (zh) 2023-10-16
CN119300835A (zh) 2025-01-10
AR128463A1 (es) 2024-05-08
CO2024011882A2 (es) 2025-01-23
TWI838114B (zh) 2024-04-01
EP4461297A1 (en) 2024-11-13
US20250134898A1 (en) 2025-05-01
KR20230120106A (ko) 2023-08-16
MX2024009854A (es) 2024-11-08

Similar Documents

Publication Publication Date Title
EP3953327B1 (en) Melanocortin-4 receptor agonists
EP4494642A1 (en) Combination therapy for preventing or treating obesity
KR102771695B1 (ko) 멜라노코르틴-4 수용체 효능제의 용도
TWI838114B (zh) 黑皮質素-4受體激動劑在預防或治療罕見遺傳性肥胖中的用途
KR20250049236A (ko) 멜라노코르틴-4 수용체의 선택적 항진제로서의 용도
RU2850792C1 (ru) Применение агониста рецептора меланокортина-4
HK40119184A (en) Use of melanocortin-4 receptor agonist in preventing or treating rare genetic obesity disease
KR20250108398A (ko) Lepr 이형접합 결핍 희귀성 유전적 비만 질환의 예방, 개선 또는 치료에서의 멜라노코르틴-4 수용체 효능제의 용도
KR20250100260A (ko) Sh2b1 결핍 희귀성 유전적 비만 질환의 예방, 개선 또는 치료에서의 멜라노코르틴-4 수용체 효능제의 용도
AU2024351762A1 (en) Use of melanocortin-4 receptor agonists for the treatment of pcsk1 deficiency indications

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260206